Purchase this article with an account.
Manuel F. Bande, María Santiago, Purificacion Mera, Josep María Piulats, María Jose Blanco, María Xosé Rodríguez-Álvarez, Carmela Capeans, Antonio Piñeiro, María Pardo; ME20-S as a Potential Biomarker for the Evaluation of Uveal Melanoma. Invest. Ophthalmol. Vis. Sci. 2015;56(12):7007-7011. doi: 10.1167/iovs.15-17183.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We previously identified the presence of the melanocyte-specific secreted (ME20-S) glycoprotein in secretomes of uveal melanoma (UM) cultures. The aim of this study was to test for the presence and levels of ME20-S in the serum of patients with choroidal nevi and UM and correlate these levels with individual clinical data.
Serum ME20-S levels were determined by ELISA in 111 patients distributed into four categories (53 choroidal nevi, 30 untreated UM, 11 10-year disease-free [DF] UM, 17 hepatic metastatic UM) and 32 age- and sex-matched controls. ME20-S levels were correlated with individual clinical data.
The UM and the metastatic groups showed significantly higher levels of serum ME20-S than the other groups (P < 0.001). ME20-S levels in the DF patients did not differ from those in the control group. In addition, log-transformed serum ME20-S levels showed a positive correlation with the thickness of the lesion mass in UM patients (regression coefficient 0.0689, 95% confidence interval 0.0689–0.1123, R2 = 27.1%).
Elevated ME20-S serum levels are associated with tumor size and advanced stages of UM while low levels are characteristic of DF patients. ME20-S might be a promising serum marker for UM and useful for monitoring metastatic disease.
This PDF is available to Subscribers Only